Trials / Completed
CompletedNCT00186576
Non-Myeloablative Allogeneic Transplant for Myelodysplastic Syndromes and Myeloproliferative Disorders
Non-Myeloablative Allogeneic Hematopoietic Cell Transplantation for Treatment of Myelodysplastic Syndromes and Myeloproliferative Disorders (Except CML)
- Status
- Completed
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 40 (estimated)
- Sponsor
- Stanford University · Academic / Other
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
To improve survival outcomes for patients with MDS and MPD with a nonmyeloablative allogeneic hematopoietic cell transplant.
Detailed description
Non-Myeloablative Allogeneic Hematopoietic Cell Transplantation for Treatment of Myelodysplastic Syndromes and Myeloproliferative Disorders (Except CML)
Conditions
- Myelodysplastic Syndromes
- Myeloproliferative Disorders
- Blood and Marrow Transplant (BMT)
- Myelodysplastic Syndromes (MDS)
- Myeloproliferative Disorders (MPD)
Interventions
| Type | Name | Description |
|---|---|---|
| PROCEDURE | nonmyeloablative allogeneic hematopoietic cell transplant |
Timeline
- Start date
- 2001-12-01
- Primary completion
- 2004-03-01
- Completion
- 2010-07-01
- First posted
- 2005-09-16
- Last updated
- 2010-10-14
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT00186576. Inclusion in this directory is not an endorsement.